Exelixis’ next franchise drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts suggested that an FDA approval is still on the table. A phase 3 trial for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results